Education
About Us
Working with TipRanks
Follow Us
Perseus Proteomics, Inc. (JP:4882)
:4882
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥203.00 - ¥1,113.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)226.58K
Market Cap
¥4.75B
Enterprise Value¥3.28B
Total Cash (Recent Filing)¥1.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.91
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.42
Shares Outstanding15,049,600
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.33
Price to Sales (P/S)87.24
P/FCF Ratio-13.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsVery high gross margins (~86–94%) indicate strong unit economics and pricing power in its proteomics offerings. Durable margins mean revenue converts to gross profit efficiently, supporting sustained R&D spend and providing room for future scale to improve operating leverage.
Debt-free Balance SheetA debt-free balance sheet materially lowers refinancing and interest-rate risk, giving the company financial flexibility while it develops products. This structural strength supports long-term R&D investment and strategic optionality despite current cash burn.
Sustained Revenue GrowthConsistent revenue growth, including positive 2025 growth, signals market adoption of its proteomics products and services. Continued top-line expansion lowers per-unit overhead over time and, paired with high gross margins, can enable meaningful operating leverage if SG&A stabilizes.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (OCF -719M; FCF -795M) demonstrates the business consumes significant cash to operate. This creates a durable financing need, limits reinvestment capacity, and increases dilution or refinancing risk unless cash generation improves materially.
Deep Ongoing LossesExtremely negative profitability (net margin -752%) shows the cost base far exceeds current revenue. Such structural unprofitability implies the company must either dramatically scale revenue or reduce structural costs to reach sustainable earnings, posing a long-term viability risk.
Declining Equity / Capital ConsumptionEquity erosion across 2022–2025 reflects cumulative losses and capital consumption. Even with no debt, shrinking equity suggests reliance on future equity financing, raising dilution risk and weakening the balance sheet, which constrains strategic flexibility over the medium term.
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥203.00 and its highest was ¥1113.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥4.75B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is May 08, 2026 which is in 59 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on Feb 13, 2026. The company reported -¥11.42 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.42.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 15,049,600 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥11.42 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.966%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Trans Genic Inc.
―
Cosmo Bio Co., Ltd.
―
ReproCELL Inc.
―
Human Metabolome Technologies, Inc.
―
Precision System Science Co.,Ltd
―
Options Prices
Currently, No data available
---